Background -Conservative treatment of malignant pericardial effusion by intrapericardial instillation of a sclerosing agent may be an alternative to surgery. Methods -Twenty patients with malignant pericardial effusion were treated by ultrasound guided pericardiocentesis and the intrapericardial instillation of mitomycin C. Results -Mitomycin C was effective in controlling the pericardial effusion in 70% of patients without causing side effects, except for pericardial constriction seven months later in one subject. Conclusions -Ultrasound guided intrapericardial instillation of mitomycin C is a suitable alternative in the management of malignant pericardial effusion.
no need for further pericardiocentesis for >30 days. The survival time was from the date of the last dose of mitomycin C to death or the last day of follow up. The effusion-free period was from the day of the last treatment to recurrence or the last follow up day.
Results
The age, sex, diagnosis, dose of mitomycin C, length of effusion-free periods, and survival time of 20 patients are presented in the table. Malignant pericardial effusion was cytologically confirmed in 17, and was strongly suspected in the other three. The effusions were bloody and there were no other causes found for the effusions.
The 20 patients drained a mean volume of 1344 ml pericardial fluid, and received one to four instillations of mitomycin C (median two) with successive instillations separated by 1-2 days. Ten survived for > 30 days without recurrence of the effusion but it recurred after 30 days in four subjects. All No complications such as pain, arrhythmias, hypotension, or fever occurred. All blood counts after mitomycin C were normal. One subject developed pericardial constriction after seven months.
Discussion
Treatment options for malignant pericardial effusion include creation of a pericardial window, systemic chemotherapy, and intrapericardial sclerosis or chemotherapy.3 [5] [6] [7] [8] Intrapericardial sclerosis or chemotherapy has recently become increasingly favoured. Agents used have included sclerosing agents such as tetracycline3 and OK-432,5 and cytotoxic drugs such as bleomycin,6 mechlorethamine, thiotepa, atabrine,4 5-fluorouracil,7 and cisplatin.8 Success rates with these cytotoxic drugs are difficult to determine because of the small numbers treated. Success rates with sclerosing agents have been high, from 91% for tetracycline3 to 100% for OK-432.5 Complications occurred relatively frequently, however, and were sometimes severe.35 A suitable alternative is mitomycin C, intrapleural instillation of which is safe and effective in controlling malignant pleural effusions.9 It was effective in controlling pericardial effusion in 14 of our 20 patients, with the treatment effective after one instillation in six, and after two in a further three patients. These results are comparable to those with tetracycline.3 We did not have a parallel group, and the numbers were small, so we cannot conclude that mitomycin C was more effective than tetracycline. However, it was well tolerated and did not cause pain, obviating the need for simultaneous injection of lignocaine, nor were there fevers, hypotension, or rapid reaccumulation of pericardial fluid which was a problem with OK-432 instillation. 5 In summary, intrapericardial instillation of mitomycin C is a safe and reasonably effective treatment for malignant pericardial effusion. Thoracic ultrasonography is useful in guiding pericardiocentesis. 
